Severe anemia in a patient with multiple sclerosis treated with natalizumab

Neurology. 2014 Jul 22;83(4):374-5. doi: 10.1212/WNL.0000000000000614. Epub 2014 Jun 18.

Authors

Anna Maria Simone¹, Diana Ferraro², Francesca Vitetta², Roberto Marasca², Goretta Bonacorsi², Giovanni Pinelli², Lucia Federzoni², Paolo Frigio Nichelli², Patrizia Sola²

Affiliations

¹ From the University of Modena and Reggio Emilia (A.M.S., D.F., F.V., R.M., G.B., L.F., P.F.N., P.S.); and Nuovo Ospedale Civile "Sant'Agostino Estense" (G.P.), Azienda Unità Sanitaria locale di Modena, Italy. annamariasimone@gmail.com.
² From the University of Modena and Reggio Emilia (A.M.S., D.F., F.V., R.M., G.B., L.F., P.F.N., P.S.); and Nuovo Ospedale Civile "Sant'Agostino Estense" (G.P.), Azienda Unità Sanitaria locale di Modena, Italy.

PMID: 24944259
DOI: 10.1212/WNL.0000000000000614

No abstract available

Publication types

Case Reports

MeSH terms

Anemia / etiology*
Anemia / pathology
Anemia / therapy
Antibodies, Monoclonal, Humanized / adverse effects*
Antibodies, Monoclonal, Humanized / therapeutic use
Blood Transfusion
Bone Marrow / pathology
Female
Follow-Up Studies
Humans
Immunosuppressive Agents / adverse effects*
Immunosuppressive Agents / therapeutic use
Integrin alpha1beta1 / antagonists & inhibitors
Middle Aged
Multiple Sclerosis, Relapsing-Remitting / complications
Multiple Sclerosis, Relapsing-Remitting / drug therapy*
Natalizumab

Substances

Antibodies, Monoclonal, Humanized
Immunosuppressive Agents
Integrin alpha1beta1
Natalizumab